ClinicalTrials.gg
CompletedNCT01064856Updated Jul 7, 2021Results posted

Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)

A Phase 3 interventional study of Adalimumab and Placebo in Peripheral Spondyloarthritis, sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-07.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study was to evaluate the efficacy and safety of adalimumab 40 mg administered every other week (eow) subcutaneously (SC) compared to placebo for 12 weeks followed by open label (OL) safety and efficacy assessments in participants with non-ankylosing spondylitis (AS), non-psoriatic arthritis (PsA) active peripheral spondyloarthritis (SpA) who have had an inadequate response to >= 2 non-steroidal anti-inflammatory drugs (NSAIDs), or are intolerant to, or have a contraindication for, NSAIDs.

02

Conditions studied

  • Peripheral Spondyloarthritis

Keywords

  • peripheral spondyloarthritis
  • adalimumab
  • humira
03

In context

Lead sponsor

AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants who had inadequate response to >= 2 non-steroidal anti-inflammatories (NSAIDs)
  • Participants who had arthritis or enthesitis or dactylitis plus: met spondyloarthritis clinical criteria
  • Negative purified protein derivative (PPD) test and Chest X-Ray performed at Baseline Visit were Negative
  • Ability to administer subcutaneous injections
  • General good health

Exclusion criteria

Exclusion Criteria:

  • Prior anti-tumor necrosis factor (TNF) therapy
  • Psoriasis or Psoriatic Arthritis
  • Fulfillment of modified New York criteria for Ankylosing Spondylitis
  • Recent infection requiring treatment
  • Significant medical events or conditions that had put patients at risk for participation
  • Female participants who were pregnant or breast-feeding or considering becoming pregnant during the study
  • History of cancer, except successfully treated skin cancer
  • Recent history of drug or alcohol abuse
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
165 participants (actual)

Study arms

  • Experimental
    Double-blind (DB) Adalimumab

    Adalimumab 40 mg subcutaneous (SC) injection every other week (eow) up to Week 12 in double-blind period.

    Biological: Adalimumab

  • Placebo comparator
    Double-blind Placebo

    Placebo subcutaneous (SC) injection every other week (eow) up to Week 12 in the double-blind period.

    Biological: Placebo

  • Experimental
    Double-blind Adalimumab / Open-label Adalimumab

    Adalimumab 40 mg SC injection eow up to Week 12 in double-blind period and from Week 12 to Week 156 in open-label period.

    Biological: Adalimumab

  • Placebo comparator
    Double-blind Placebo / Open-label Adalimumab

    Placebo SC injection every other week (eow) up to Week 12 in the double-blind period; adalimumab 40 mg subcutaneous injection eow from Week 12 to Week 156 in the open-label period.

    Biological: Adalimumab · Biological: Placebo

Interventions

  • BiologicalAdalimumab

    Study drug was provided as a sterile SC injection solution in 1 mL pre-filled syringes containing adalimumab 40 mg/0.8 mL. Study drug was SC self-administered eow at approximately the same time of day.

    Also known as: ABT-D2E7, Humira

  • BiologicalPlacebo

    Study drug was provided as a sterile SC injection solution in 1 mL pre-filled syringes containing matching placebo for adalimumab. Study drug was SC self-administered eow at approximately the same time of day.

06

What researchers measure

Primary outcomes

  1. Percentage of Responders According to the Composite Peripheral SpA Response Criteria (PSpARC 40) at Week 12

    Percentage of participants achieving the following composite response at Week 12: \>= 40% improvement (minimum 20 mm absolute improvement) from Baseline in Patient Global Assessment (PTGA) of Disease Activity as measured by a 100 mm visual analogue scale (VAS) where 0=no symptoms and 100=maximum symptoms; \>= 40% improvement (minimum 20 mm absolute improvement) from Baseline in PTGA - Pain as measured by a 100 mm VAS where 0=no pain and 100=maximum pain; and \>= 40% improvement from Baseline in at least 1 of the following 3 criteria: swollen joint count (76 joints) and tender joint count (78 joints); total enthesitis count; or total dactylitis count. Non-responder imputation: missing response was imputed as non-response.

    Time frame: Week 12

  2. Number of Participants With Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with treatment. If an adverse event meets any of the following criteria, it is considered a serious adverse event (SAE): results in death or is life-threatening, results in admission or prolongation of hospitalization, results in congenital anomaly or persistent or significant disability/incapacity, or is an important medical event requiring medical or surgical intervention to prevent serious outcome. AEs were categorized by severity (mild, moderate, severe) and relationship to treatment (probably, possibly, probably not, not related). Please see Adverse Events section below for more details.

    Time frame: Baseline (day of first study drug administration) through Week 156 plus 70 days

Secondary outcomes

  1. Change From Baseline in Physician Global Assessment (PGA) of Disease Activity at Week 12

    A VAS was to be used for the Physician Global Assessment (PGA) of disease activity (current status). The left end of the VAS scale (0 mm) signifies the absence of symptoms and the right end (100 mm) signifies maximum disease activity. Last observation carried forward (LOCF): missing values were imputed using the last non-missing post-baseline value prior to the missing value.

    Time frame: Baseline (last measurement prior to first DB dose), Week 12

  2. Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 12

    The BASDAI was to be completed at the designated study visits. The participant was to assess his/her disease activity using the BASDAI which consisted of a VAS scale used to answer 6 questions (Q1 through Q6) pertaining to symptoms experienced by the participant for the past week. Each question on the BASDAI was reported in centimeters (0 \[none\] to 10 \[very severe\] with one question's possible answers being in time increments \[0 hours to ≥ 2 hours\]). The overall BASDAI score ranges from 0 to 10 cm and was calculated as follows: BASDAI Score = 0.2 × (Q1 + Q2 + Q3 + Q4 + Q5/2 + Q6/2). Lower scores indicate less disease activity. LOCF: Missing value was imputed using the last non-missing post-baseline value prior to missing value.

    Time frame: Baseline (last measurement prior to first DB dose), Week 12

  3. Change From Baseline in Health Assessment Questionnaire Modified for the Spondyloarthropathies (HAQ-S) Total at Week 12

    The HAQ-S is a self-reported measure to assess the physical function and health-related quality of life. The Disability Index (DI) of HAQ-S is calculated as the mean of the following 8 category scores (range: 0 \[without any difficulty\] to 3 \[unable to do\]): Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. Five additional items in the functional status measure were included in the HAQ-S, including carrying heavy packages, sitting for long periods, able to work at a flat topped table, and (if the participant had a driver's license or a car) able to look in the rear view mirror and able to turn head to drive in reverse. The overall score ranges from 0 (no disability) to 3 (three very severe, high-dependency disability). Negative mean changes from Baseline in the overall score indicate improvement. LOCF: Missing value was imputed using the last non-missing post-baseline value prior to missing value.

    Time frame: Baseline (last measurement prior to first DB dose), Week 12

  4. Change From Baseline in Short Form-36 Health Status Survey™ Version 2 (SF-36™V2) Physical Component Score (PCS) at Week 12

    The Short Form-36 Health Status Survey™ Version 2 (SF-36™V2) is a 36-item generic health-related quality of life measure to assess the participant's view of their health consisting of 2 components: physical and mental. For each component, a transformed summary score is calculated using 8 sub-domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Scores range from 0 to 100. Higher scores indicate a better health state.

    Time frame: Baseline (last measurement prior to first DB dose), Week 12

  5. Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Week 12

    Assessment of enthesitis was performed in the following 7 domains: 1) 1st costochondral joint left and right, 2) 7th costochondral joint left and right, 3) posterior superior iliac spine left and right, 4) anterior superior iliac spine left and right, 5) iliac crest left and right, 6) 5th lumbar spinous process and 7) proximal insertion of Achilles tendon left and right. Each domain was graded for the presence (1) or absence (0) of tenderness yielding total MASES ranging from 0 (0 sites with tenderness) to 13 (worst possible score; 13 sites with tenderness). Participants with non-missing Baseline and at least 1 non-missing post-Baseline value were included in post-Baseline visits. LOCF: missing value was imputed using the last non-missing post-Baseline value prior to missing value.

    Time frame: Baseline (last measurement prior to first DB dose), Week 12

  6. Change From Baseline in Leeds Enthesitis Index at Week 12

    Assessment of enthesitis was performed in the following 6 domains: left and right lateral epicondyle, left and right medial femoral condyle, left and right Achilles tendon insertion. Tenderness at each site was quantified on a dichotomous basis: Each domain was graded for the presence (1) and absence (0) of tenderness yielding total Leeds Enthesitis Index scores ranging from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Participants with non-missing Baseline and at least 1 non-missing post-Baseline value were included in post-Baseline visits. LOCF: missing value was imputed using the last non-missing post-Baseline value prior to missing value.

    Time frame: Baseline (last measurement prior to first DB dose), Week 12

  7. Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Score at Week 12

    Assessment of enthesitis was performed in the following 16 domains: left and right (L/R) medial epicondyle; L/R lateral epicondyle; L/R supraspinatus insertion into the greater tuberosity of humerus; L/R greater trochanter; L/R quadriceps insertion into superior border of patella; L/R patellar ligament insertion into inferior pole of patella or tibial tubercle; L/R Achilles tendon insertion into calcaneum; L/R plantar fascia insertion into calcaneum. Tenderness at each site was quantified on a dichotomous basis. Each domain was graded for the presence (1) and absence (0) of tenderness yielding total SPARCC scores ranging from 0 (0 sites with tenderness) to 16 (worst possible score; 16 sites with tenderness). Participants with non-missing Baseline and at least 1 non-missing post-Baseline value were included in post-Baseline visits. LOCF: missing value was imputed using the last non-missing post-Baseline value prior to missing value.

    Time frame: Baseline (last measurement prior to first DB dose), Week 12

  8. Change From Baseline in Dactylitis at Week 12

    Assessment of the presence or absence of dactylitis as well as grading of tenderness and swelling in all 20 of the participants' digits was performed. Tenderness at each site was quantified from absent to severe. Swelling was quantified from mild to severe. Total Dactylitis Assessment scores ranging from 0 (no digits with dactylitis) to 20 (worst possible score; 20 digits with dactylitis). Participants with non-missing Baseline and at least 1 non-missing post-Baseline value were included in post-Baseline visits. LOCF: missing value was imputed using the last non-missing post-Baseline value prior to missing value.

    Time frame: Baseline (last measurement prior to first DB dose), Week 12

  9. Change From Baseline in Tender Joint Count (TJC) at Week 12

    Seventy-eight joints were assessed for tenderness by physical examination. Tenderness of each joint was classified as present (1) or absent (0), for a total possible TJC score of 0 (0 joints with tenderness) to 78 (worst possible score/78 joints with tenderness). Participants with non-missing Baseline and at least 1 non-missing post-Baseline value were included in post-Baseline visits. LOCF: missing value was imputed using the last non-missing post-Baseline value prior to missing value.

    Time frame: Baseline (last measurement prior to first DB dose), Week 12

  10. Change From Baseline in Swollen Joint Count (SJC) at Week 12

    Seventy-six joints were assessed for swelling by physical examination. Swelling of each joint was classified as present (1) or absent (0), for a total possible score SJC of 0 (0 joints with swelling) to 76 (worst possible score/76 joints with swelling). Participants with non-missing Baseline and at least 1 non-missing post-Baseline value were included in post-Baseline visits. LOCF: missing value was imputed using the last non-missing post-Baseline value prior to missing value.

    Time frame: Baseline (last measurement prior to first DB dose), Week 12

  11. Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12

    The ASDAS is a continuous disease activity score: low score indicates lower disease activity and higher values indicate higher disease activity. The score ranges from 0 to no defined upper limit. It is categorized into 4 disease activity states based on score: inactive disease (\< 1.3), moderate (≥ 1.3 to \< 2.1), high (≥ 2.1 to ≤ 3.5), and very high (\> 3.5). Clinically important and major improvements in ASDAS are defined as a reduction from Baseline of ≥ 1.1 and ≥ 2.0 points, respectively. Participants with non-missing Baseline and at least 1 non-missing post-Baseline value were included in post-Baseline visits. LOCF: missing value was imputed using the last non-missing post-Baseline value prior to missing value.

    Time frame: Baseline (last measurement prior to first DB dose), Week 12

07

Results

Posted Nov 25, 2016

Participant flow

Double-blind (DB) Period
Participant flow — Double-blind (DB) Period
MilestoneDouble-blind (DB) AdalimumabDouble-blind PlaceboDouble-blind Adalimumab / Open-label AdalimumabDouble-blind Placebo / Open-label Adalimumab
Started848100
Completed828100
Not completed2000
Withdrew: Adverse event1000
Withdrew: Consent withdrawn by participant1000
Open-label (OL) Period
Participant flow — Open-label (OL) Period
MilestoneDouble-blind (DB) AdalimumabDouble-blind PlaceboDouble-blind Adalimumab / Open-label AdalimumabDouble-blind Placebo / Open-label Adalimumab
Started008281
Completed005661
Not completed002620
Withdrew: Adverse event00126
Withdrew: Consent withdrawn by participant0056
Withdrew: Lost to follow-up0021
Withdrew: Other0077

Outcome measures

PrimaryPercentage of Responders According to the Composite Peripheral SpA Response Criteria (PSpARC 40) at Week 12

Percentage of participants achieving the following composite response at Week 12: \>= 40% improvement (minimum 20 mm absolute improvement) from Baseline in Patient Global Assessment (PTGA) of Disease Activity as measured by a 100 mm visual analogue scale (VAS) where 0=no symptoms and 100=maximum symptoms; \>= 40% improvement (minimum 20 mm absolute improvement) from Baseline in PTGA - Pain as measured by a 100 mm VAS where 0=no pain and 100=maximum pain; and \>= 40% improvement from Baseline in at least 1 of the following 3 criteria: swollen joint count (76 joints) and tender joint count (78 joints); total enthesitis count; or total dactylitis count. Non-responder imputation: missing response was imputed as non-response.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Responders According to the Composite Peripheral SpA Response Criteria (PSpARC 40) at Week 12
percentage of participantsDouble-blind (DB) AdalimumabDouble-blind Placebo
Responder39.319.8
Non-responder60.780.2
Statistical analysis
  • Double-blind (DB) Adalimumab vs Double-blind Placebo · Pearson's chi-square · p = 0.006
PrimaryNumber of Participants With Adverse Events

An adverse event (AE) is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with treatment. If an adverse event meets any of the following criteria, it is considered a serious adverse event (SAE): results in death or is life-threatening, results in admission or prolongation of hospitalization, results in congenital anomaly or persistent or significant disability/incapacity, or is an important medical event requiring medical or surgical intervention to prevent serious outcome. AEs were categorized by severity (mild, moderate, severe) and relationship to treatment (probably, possibly, probably not, not related). Please see Adverse Events section below for more details.

Time frame:
Baseline (day of first study drug administration) through Week 156 plus 70 days
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsDouble-blind (DB) AdalimumabDouble-blind Placebo
Any adverse event4745
Any serious adverse event11
Any AE leading to discontinuation of study drug30
Any severe AE42
Any AE at least possibly drug related2115
Any SAE at least possibly drug related00
Any infection1824
SecondaryChange From Baseline in Physician Global Assessment (PGA) of Disease Activity at Week 12

A VAS was to be used for the Physician Global Assessment (PGA) of disease activity (current status). The left end of the VAS scale (0 mm) signifies the absence of symptoms and the right end (100 mm) signifies maximum disease activity. Last observation carried forward (LOCF): missing values were imputed using the last non-missing post-baseline value prior to the missing value.

Time frame:
Baseline (last measurement prior to first DB dose), Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Physician Global Assessment (PGA) of Disease Activity at Week 12
units on a scaleDouble-blind (DB) AdalimumabDouble-blind Placebo
Change From Baseline in Physician Global Assessment (PGA) of Disease Activity at Week 12-32.2 ± 22.52-18.2 ± 22.93
Statistical analysis
  • Double-blind (DB) Adalimumab vs Double-blind Placebo · ANCOVA · p = <0.001The P-value was based on an ANCOVA model adjusting for baseline with treatment as a factor.
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 12

The BASDAI was to be completed at the designated study visits. The participant was to assess his/her disease activity using the BASDAI which consisted of a VAS scale used to answer 6 questions (Q1 through Q6) pertaining to symptoms experienced by the participant for the past week. Each question on the BASDAI was reported in centimeters (0 \[none\] to 10 \[very severe\] with one question's possible answers being in time increments \[0 hours to ≥ 2 hours\]). The overall BASDAI score ranges from 0 to 10 cm and was calculated as follows: BASDAI Score = 0.2 × (Q1 + Q2 + Q3 + Q4 + Q5/2 + Q6/2). Lower scores indicate less disease activity. LOCF: Missing value was imputed using the last non-missing post-baseline value prior to missing value.

Time frame:
Baseline (last measurement prior to first DB dose), Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 12
units on a scaleDouble-blind (DB) AdalimumabDouble-blind Placebo
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 12-2.1 ± 2.32-1 ± 2.19
Statistical analysis
  • Double-blind (DB) Adalimumab vs Double-blind Placebo · ANCOVA · p = 0.003The P-value was based on an ANCOVA model adjusting for baseline with treatment as a factor.
SecondaryChange From Baseline in Health Assessment Questionnaire Modified for the Spondyloarthropathies (HAQ-S) Total at Week 12

The HAQ-S is a self-reported measure to assess the physical function and health-related quality of life. The Disability Index (DI) of HAQ-S is calculated as the mean of the following 8 category scores (range: 0 \[without any difficulty\] to 3 \[unable to do\]): Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. Five additional items in the functional status measure were included in the HAQ-S, including carrying heavy packages, sitting for long periods, able to work at a flat topped table, and (if the participant had a driver's license or a car) able to look in the rear view mirror and able to turn head to drive in reverse. The overall score ranges from 0 (no disability) to 3 (three very severe, high-dependency disability). Negative mean changes from Baseline in the overall score indicate improvement. LOCF: Missing value was imputed using the last non-missing post-baseline value prior to missing value.

Time frame:
Baseline (last measurement prior to first DB dose), Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Health Assessment Questionnaire Modified for the Spondyloarthropathies (HAQ-S) Total at Week 12
units on a scaleDouble-blind (DB) AdalimumabDouble-blind Placebo
Change From Baseline in Health Assessment Questionnaire Modified for the Spondyloarthropathies (HAQ-S) Total at Week 12-0.3 ± 0.44-0.2 ± 0.47
Statistical analysis
  • Double-blind (DB) Adalimumab vs Double-blind Placebo · ANCOVA · p = 0.051The P-value was based on an ANCOVA model adjusting for baseline with treatment as a factor.
SecondaryChange From Baseline in Short Form-36 Health Status Survey™ Version 2 (SF-36™V2) Physical Component Score (PCS) at Week 12

The Short Form-36 Health Status Survey™ Version 2 (SF-36™V2) is a 36-item generic health-related quality of life measure to assess the participant's view of their health consisting of 2 components: physical and mental. For each component, a transformed summary score is calculated using 8 sub-domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Scores range from 0 to 100. Higher scores indicate a better health state.

Time frame:
Baseline (last measurement prior to first DB dose), Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Short Form-36 Health Status Survey™ Version 2 (SF-36™V2) Physical Component Score (PCS) at Week 12
units on a scaleDouble-blind (DB) AdalimumabDouble-blind Placebo
Change From Baseline in Short Form-36 Health Status Survey™ Version 2 (SF-36™V2) Physical Component Score (PCS) at Week 126.7 ± 7.852.4 ± 6.65
SecondaryChange From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Week 12

Assessment of enthesitis was performed in the following 7 domains: 1) 1st costochondral joint left and right, 2) 7th costochondral joint left and right, 3) posterior superior iliac spine left and right, 4) anterior superior iliac spine left and right, 5) iliac crest left and right, 6) 5th lumbar spinous process and 7) proximal insertion of Achilles tendon left and right. Each domain was graded for the presence (1) or absence (0) of tenderness yielding total MASES ranging from 0 (0 sites with tenderness) to 13 (worst possible score; 13 sites with tenderness). Participants with non-missing Baseline and at least 1 non-missing post-Baseline value were included in post-Baseline visits. LOCF: missing value was imputed using the last non-missing post-Baseline value prior to missing value.

Time frame:
Baseline (last measurement prior to first DB dose), Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Week 12
units on a scaleDouble-blind (DB) AdalimumabDouble-blind Placebo
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Week 12-1.2 ± 2.67-0.8 ± 2.38
SecondaryChange From Baseline in Leeds Enthesitis Index at Week 12

Assessment of enthesitis was performed in the following 6 domains: left and right lateral epicondyle, left and right medial femoral condyle, left and right Achilles tendon insertion. Tenderness at each site was quantified on a dichotomous basis: Each domain was graded for the presence (1) and absence (0) of tenderness yielding total Leeds Enthesitis Index scores ranging from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Participants with non-missing Baseline and at least 1 non-missing post-Baseline value were included in post-Baseline visits. LOCF: missing value was imputed using the last non-missing post-Baseline value prior to missing value.

Time frame:
Baseline (last measurement prior to first DB dose), Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Leeds Enthesitis Index at Week 12
units on a scaleDouble-blind (DB) AdalimumabDouble-blind Placebo
Change From Baseline in Leeds Enthesitis Index at Week 12-0.8 ± 1.28-0.1 ± 1.19
SecondaryChange From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Score at Week 12

Assessment of enthesitis was performed in the following 16 domains: left and right (L/R) medial epicondyle; L/R lateral epicondyle; L/R supraspinatus insertion into the greater tuberosity of humerus; L/R greater trochanter; L/R quadriceps insertion into superior border of patella; L/R patellar ligament insertion into inferior pole of patella or tibial tubercle; L/R Achilles tendon insertion into calcaneum; L/R plantar fascia insertion into calcaneum. Tenderness at each site was quantified on a dichotomous basis. Each domain was graded for the presence (1) and absence (0) of tenderness yielding total SPARCC scores ranging from 0 (0 sites with tenderness) to 16 (worst possible score; 16 sites with tenderness). Participants with non-missing Baseline and at least 1 non-missing post-Baseline value were included in post-Baseline visits. LOCF: missing value was imputed using the last non-missing post-Baseline value prior to missing value.

Time frame:
Baseline (last measurement prior to first DB dose), Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Score at Week 12
units on a scaleDouble-blind (DB) AdalimumabDouble-blind Placebo
Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Score at Week 12-1.7 ± 2.43-0.7 ± 2.21
SecondaryChange From Baseline in Dactylitis at Week 12

Assessment of the presence or absence of dactylitis as well as grading of tenderness and swelling in all 20 of the participants' digits was performed. Tenderness at each site was quantified from absent to severe. Swelling was quantified from mild to severe. Total Dactylitis Assessment scores ranging from 0 (no digits with dactylitis) to 20 (worst possible score; 20 digits with dactylitis). Participants with non-missing Baseline and at least 1 non-missing post-Baseline value were included in post-Baseline visits. LOCF: missing value was imputed using the last non-missing post-Baseline value prior to missing value.

Time frame:
Baseline (last measurement prior to first DB dose), Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Dactylitis at Week 12
units on a scaleDouble-blind (DB) AdalimumabDouble-blind Placebo
Change From Baseline in Dactylitis at Week 12-0.2 ± 1.050.3 ± 0.93
SecondaryChange From Baseline in Tender Joint Count (TJC) at Week 12

Seventy-eight joints were assessed for tenderness by physical examination. Tenderness of each joint was classified as present (1) or absent (0), for a total possible TJC score of 0 (0 joints with tenderness) to 78 (worst possible score/78 joints with tenderness). Participants with non-missing Baseline and at least 1 non-missing post-Baseline value were included in post-Baseline visits. LOCF: missing value was imputed using the last non-missing post-Baseline value prior to missing value.

Time frame:
Baseline (last measurement prior to first DB dose), Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Tender Joint Count (TJC) at Week 12
units on a scaleDouble-blind (DB) AdalimumabDouble-blind Placebo
Change From Baseline in Tender Joint Count (TJC) at Week 12-5.9 ± 8.67-1.8 ± 8.41
SecondaryChange From Baseline in Swollen Joint Count (SJC) at Week 12

Seventy-six joints were assessed for swelling by physical examination. Swelling of each joint was classified as present (1) or absent (0), for a total possible score SJC of 0 (0 joints with swelling) to 76 (worst possible score/76 joints with swelling). Participants with non-missing Baseline and at least 1 non-missing post-Baseline value were included in post-Baseline visits. LOCF: missing value was imputed using the last non-missing post-Baseline value prior to missing value.

Time frame:
Baseline (last measurement prior to first DB dose), Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Swollen Joint Count (SJC) at Week 12
units on a scaleDouble-blind (DB) AdalimumabDouble-blind Placebo
Change From Baseline in Swollen Joint Count (SJC) at Week 12-3.6 ± 4.27-3.1 ± 5.64
SecondaryChange From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12

The ASDAS is a continuous disease activity score: low score indicates lower disease activity and higher values indicate higher disease activity. The score ranges from 0 to no defined upper limit. It is categorized into 4 disease activity states based on score: inactive disease (\< 1.3), moderate (≥ 1.3 to \< 2.1), high (≥ 2.1 to ≤ 3.5), and very high (\> 3.5). Clinically important and major improvements in ASDAS are defined as a reduction from Baseline of ≥ 1.1 and ≥ 2.0 points, respectively. Participants with non-missing Baseline and at least 1 non-missing post-Baseline value were included in post-Baseline visits. LOCF: missing value was imputed using the last non-missing post-Baseline value prior to missing value.

Time frame:
Baseline (last measurement prior to first DB dose), Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12
units on a scaleDouble-blind (DB) AdalimumabDouble-blind Placebo
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12-1.0 ± 1.07-0.5 ± 0.90

Adverse events

Collected over Baseline (day of first study drug administration) through Week 156 plus 70 days.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-blind Placebo—1/81 (1.2%)33/81 (40.7%)
Double-blind Adalimumab—1/84 (1.2%)30/84 (35.7%)
Any Adalimumab—24/165 (14.5%)139/165 (84.2%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventDouble-blind PlaceboDouble-blind AdalimumabAny Adalimumab
SPONDYLOARTHROPATHYMusculoskeletal and connective tissue disorders0/810/843/165
CHEST PAINGeneral disorders1/810/840/165
OVERDOSEInjury, poisoning and procedural complications0/811/841/165
CORONARY ARTERY DISEASECardiac disorders0/810/841/165
ABDOMINAL HERNIAGastrointestinal disorders0/810/841/165
ANAL FISTULAGastrointestinal disorders0/810/841/165
COLITISGastrointestinal disorders0/810/841/165
CROHN'S DISEASEGastrointestinal disorders0/810/841/165
CELLULITISInfections and infestations0/810/841/165
DIVERTICULITISInfections and infestations0/810/841/165
Most frequent other events
Showing 10 of 40
Most frequent other events
EventDouble-blind PlaceboDouble-blind AdalimumabAny Adalimumab
NASOPHARYNGITISInfections and infestations11/814/8451/165
SPONDYLOARTHROPATHYMusculoskeletal and connective tissue disorders4/816/8442/165
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations4/814/8430/165
BRONCHITISInfections and infestations2/811/8423/165
HEADACHENervous system disorders3/814/8417/165
DIARRHOEAGastrointestinal disorders4/811/8415/165
SINUSITISInfections and infestations1/811/8415/165
OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders3/813/8415/165
FATIGUEGeneral disorders1/811/8414/165
RHINITISInfections and infestations0/811/8413/165

Baseline characteristics

Efficacy analyses included all participants who were randomized and received at least 1 dose of double-blind study drug (ITT).

Age, Continuous
Age, Continuous(years)Double-blind (DB) AdalimumabDouble-blind PlaceboTotal
Mean42.5 ± 10.7938.5 ± 12.7740.6 ± 11.94
Sex: Female, Male
Sex: Female, Male(Participants)Double-blind (DB) AdalimumabDouble-blind PlaceboTotal
Female484290
Male363975
Tender Joint Count (78 Joints)
Tender Joint Count (78 Joints)(units on a scale)Double-blind (DB) AdalimumabDouble-blind PlaceboTotal
Mean12.95 ± 12.7913.62 ± 16.1013.28 ± 14.46
Swollen Joint Count (76 Joints)
Swollen Joint Count (76 Joints)(units on a scale)Double-blind (DB) AdalimumabDouble-blind PlaceboTotal
Mean6.12 ± 5.587.31 ± 7.996.70 ± 6.87
Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)
Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)(units on a scale)Double-blind (DB) AdalimumabDouble-blind PlaceboTotal
Mean3.13 ± 3.603.59 ± 3.393.36 ± 3.50
Leeds Enthesitis Index
Leeds Enthesitis Index(units on a scale)Double-blind (DB) AdalimumabDouble-blind PlaceboTotal
Mean1.49 ± 1.661.42 ± 1.611.45 ± 1.63
Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Score
Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Score(units on a scale)Double-blind (DB) AdalimumabDouble-blind PlaceboTotal
Mean3.83 ± 4.034.05 ± 3.783.94 ± 3.90
Total Enthesitis Count
Total Enthesitis Count(units on a scale)Double-blind (DB) AdalimumabDouble-blind PlaceboTotal
Mean6.73 ± 6.957.33 ± 6.697.02 ± 6.81

7 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Mease P, Sieper J, Van den Bosch F, Rahman P, Karunaratne PM, Pangan AL. Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis. Arthritis Rheumatol. 2015 Apr;67(4):914-23. doi: 10.1002/art.39008. PubMed 25545240 ↗
  • Coates LC, Abraham S, Tillett W, Mease PJ, Ramiro S, Wu T, Wang X, Pangan AL, Song IH. Performance and Predictors of Minimal Disease Activity Response in Patients With Peripheral Spondyloarthritis Treated With Adalimumab. Arthritis Care Res (Hoboken). 2022 Feb;74(2):259-267. doi: 10.1002/acr.24442. Epub 2021 Dec 29. PubMed 32937016 ↗
  • Mease PJ, Van den Bosch F, Sieper J, Xia Y, Pangan AL, Song IH. Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab. J Rheumatol. 2017 May;44(5):599-608. doi: 10.3899/jrheum.160387. Epub 2017 Mar 15. PubMed 28298558 ↗
  • Turina MC, Ramiro S, Baeten DL, Mease P, Paramarta JE, Song IH, Pangan AL, Landewe R. A psychometric analysis of outcome measures in peripheral spondyloarthritis. Ann Rheum Dis. 2016 Jul;75(7):1302-7. doi: 10.1136/annrheumdis-2014-207235. Epub 2015 Aug 5. PubMed 26245756 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of Aug 2011 and a completion of May 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 5 years 3 months after primary completion. A results delay was requested in Aug 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2010
First posted
Feb 9, 2010
Start
Feb 2010
Primary completionActual
Aug 2011
CompletionActual
May 2014
Results delay requested
Aug 10, 2012
Results first posted
Nov 25, 2016
Last update
Jul 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01064856
Responsible party
Sponsor
First posted
Feb 9, 2010
Start date
Feb 2010
Primary completion
Aug 2011
Completion
May 2014
Results posted
Nov 25, 2016
Last update
Jul 7, 2021

Study contacts

In-Ho Song, MD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion